Phase 2 results of a squamous cell carcinoma of the head and neck monotherapy clinical trail were recently presented by pharmaceutical companies Seagen and Genmab.
The trial analyzes individuals with squamous cell carcinoma of the head and neck who experienced disease progression on or after first-line platinum-containing regimen and checkpoint. Preliminary results discuss the monotherapy "tisotumab vedotin", according to a press release by Seagen.
Preliminary findings indicated that isotumab vedotin appears to be a manageable safety profile, according to the release.
“We recognize the high medical need for additional treatment options for patients with head and neck cancers,” Jan van de Winkel, CEO of Genmab said, according to the release. “These initial data results are encouraging and underscore the importance of our ongoing clinical trial program that will assess the potential utility of tisotumab vedotin in various cancers.”
The trial included 31 patients with an average age of 65. According to the release, patients received 2 milligrams of tsiotuab vedotin through an IV on day one of every 21-day cycle, according to the release.
The results were presented at a Multidisciplinary Head and Neck Cancers Symposium on Feb. 25, according to the release.
“The presentation of these preliminary data represents another step forward in our work to advance the tisotumab vedotin development program,” Dr. Roger Dansey, chief medical officer of Seagen said, according to the release. “In partnership with Genmab, we will continue to recruit additional patients for trials to further investigate tisotumab vedotin in patients with squamous cell carcinoma of the head and neck, including its potential use as a combination therapy.”
According to the release, TIVDAK is used to treat adults with recurring or metastatic cervical cancer who experience disease progression during or after chemotherapy.
Possible adverse reactions of tisotumab vedotin include, but are not limited to, ocular toxicity such as severe vision loss, corneal ulceration, dry eye and blepharitis; peripheral neuropathy; hemorrhage; pneumonitis; and embryo-fetal toxicity. The release states that severe adverse reactions occurred in 43% of patients.